الفهرس 
Title : Expression of programmed death legend (PD-L1) in laryngeal (Histopathological and immunohistochemical study)
AbstractOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
Laryngeal Carcinoma is the second most common malignancy of the head and neck squamous cell carcinoma.Based on insight into immune system / cancer interactions, cancer immunotherapy strategies have been developed. Of these strategies, immune checkpoints regulators are among the most important. Programmed Death Ligand 1 (PD-L1) is one of the 2 ligands of Programmed Death-1 (PD-1); an important immune checkpoint regulator. Clinical trials using PD-L1 antibodies have shown efficacy in various cancers.
Objectives:Detection of immunohistochemical (IHC) expression of PD-L1 by carcinoma cells (Ca) and immune cells (ICs)in laryngeal squamous cell carcinoma , to investigate the possibility of using it as a targeted therapy, as well as, correlation of this expression with the clinico-pathologic parameters of the tumors.
Materials and methods:forty laryngeal squamous cell carcinoma tissue sections were collected from laryngectomy specimens. IHC expression of PD-L1 was investigated in Ca and ICs.
Results: ICs PDL1 expression was detected in of 67.5% of cases and showed glottictumor cases was significantly higher than in the transglottic, supraglottic and subglottic cases. (P <0.05).Carcinoma cells PDL1 expression was detected in 22.5% ,and there is no significant relation between the score and age, sex, tumor site, grade, cartilage infiltration, tumor grade, lymph node grade, stage, Tils, and PDL1 score in immune (P.>0.05)
Conclusion: Our results supported PD-L1 expression inLaryngeal Carcinomaby both carcinoma cells and ICs, with higher expression in subset of tumors that are high grade, TILs rich .